Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221146133
Abstract: Background: The single-arm phase II APT trial established trastuzumab and paclitaxel (TH) as the standard adjuvant regimen for small human epidermal growth factor receptor 2 (HER2+) tumors. However, paclitaxel causes alopecia and has high rates… read more here.
Keywords: stage her2; early stage; breast cancer; stage ... See more keywords
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.03398
Abstract: PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I… read more here.
Keywords: trastuzumab emtansine; breast cancer; trastuzumab; trial ... See more keywords
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.549
Abstract: 549Background: ExteNET, an international, randomized, placebo-controlled phase III trial, showed that neratinib given for 1 year after trastuzumab-based adjuvant therapy significantly improved 2- (HR 0.67, p = 0.009) and 5-year (HR 0.73, p = 0.008)… read more here.
Keywords: trastuzumab based; trastuzumab; breast cancer; early stage ... See more keywords
A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e12600
Abstract: e12600 Background: In early-stage HER2+ breast cancer (BC), escalation or de-escalation of systemic treatment is an unmet need. Integration of promising biomarkers into risk scoring will further help progressing in the field. We aim to… read more here.
Keywords: low risk; risk; signature; early stage ... See more keywords